BioSpace News Archive

LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q2 2020 results and announced a $0.095/share quarterly dividend. Q2 2020 Results Sales of $24.9mm, -16% (-24% organic) vs. Q2 2019 Op. income of $4.9mm, -18% Adjusted op. income of $6.1mm, +3% (excludes acquisition-related special items) Operating margin of 20% Net income of $3.5mm, -24% Earnings of $0.17 per diluted share,

Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”) today announced that it will be presenting at the YAFO ACCESS CHINA - 2020 Summer Online Partnering Day on Thursday, July 30 at 10:00 pm EST. Dr. Marc Hedrick, President and CEO of Plus Therapeutics, will be hosting the presentation and answering questions from investors. To access the live presentation, please use the following information: YAFO ACCESS CHINA Partnering Conference

Akumin Inc. (TSX: AKU) (TSX: AKU.U) (" Akumin " or the " Company ") will host a conference call at 8:30 a.m. Eastern Time , August 13, 2020 , to discuss its second quarter 2020 financial results. To access the conference call, dial toll-free in Canada or the U.S. 888-231-8191 or, for international callers, 647-427

Menarini licenses global development and commercialization rights of elacestrant, an oral SERD currently in late stage Phase 3 development

Health Canada is providing an update on the status of ranitidine drugs in Canada, including enhanced safety measures the Department is putting in place to detect an impurity called N-nitrosodimethylamine.

Study suggests GenScript’s cPass™ test is faster, better and safer than traditional tests

Inozyme Pharma, Inc. (“Inozyme”) (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization, today announced the pricing of its initial public offering of 7,000,000 shares of common stock at a public offering price of $16.00 per share, for gross proceeds of $112.0 million,

Internationally renowned clinical-stage immune cell and gene therapy company, Gracell Biotechnologies Co., Ltd. (“Gracell” or “the Company”) has announced two appointments to the executive suite.

The Foundation for Opioid Response Efforts (FORE) today announced it is providing grants to six organizations nationwide to help them respond to increased risks faced by individuals with opioid use disorder and an alarming increase in overdoses during the COVID-19 pandemic.

The healthcare industry has made significant progress when it comes to efficiency and scope in the last several years, yet many complex issues remain unsolved.